Intercept Pharmaceuticals Names Cambridge BioMarketing Agency of Record for Obeticholic Acid
Intercept Pharmaceuticals Names Cambridge BioMarketing Agency of Record for Obeticholic Acid (OCA)
CAMBRIDGE, Mass. – Intercept Pharmaceuticals, Inc. based in New York and San Diego California has named Cambridge BioMarketing (CB), a full-service healthcare marketing communications agency focused on orphan and specialty pharmaceuticals, as agency of record for the expected launch of obeticholic acid, or OCA. The product is a bile acid analog and first-in-class FXR agonist currently in Phase III clinical development for the treatment of primary biliary cirrhosis (PBC).
The account, previously unassigned, was awarded based on the agency’s experience in rare diseases with unmet medical needs. Billings were not disclosed.
Intercept Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases, such as primary biliary cirrhosis, utilizing its expertise in bile acid chemistry. The company’s product candidates have the potential to treat orphan and more prevalent liver diseases for which there currently are limited therapeutic solutions.
PBC is a liver disease that resulting in persistent toxic build-up of bile acids which causes progressive liver damage marked by chronic inflammation and fibrosis. While PBC is rare, it is the most common cholestatic liver disease. An estimated 90% of patients are women, with approximately one in 1,000 women over the age of 40 afflicted by the disease.
About Cambridge BioMarketing
Founded in 2001, Cambridge BioMarketing is the world’s leading orphan and specialty communications agency. Having launched some of the most successful orphan and ultra-orphan products ever, the Cambridge culture reflects its clients’ extraordinary drive to deliver life-changing medicines to those who need them most: people and families facing devastating, underappreciated diseases. For more information about the agency and its mission, please visit www.cambridgebmg.com.
Posted: September 2013